In this study we investigated the anti-cancer properties of CK-3 (Figure 1A), a dual inhibitor of the PI3K/AKT/mTOR and MAPK/ERK pathways, on multiple HCC cell lines. This evidence concerns the gene AKT1 and hepatocellular carcinoma.